Keyphrases
Patient Management
100%
Low-grade Glioma
100%
Evidence-based Clinical Practice Guideline
100%
Diffuse Low-grade Glioma
100%
Overall Survival
42%
Absence of Evidence
42%
IDH mutation
42%
Carboplatin
42%
Oligodendroglioma
42%
Glioma Recurrence
42%
Clinical Trials
28%
Clinical Symptoms
28%
Temozolomide
28%
Malignant Transformation
28%
Proliferative Index
28%
Re-irradiation
28%
MGMT Status
28%
Chemotherapy
14%
Tumor
14%
Disease Control
14%
Recurrence Rate
14%
Progression-free Survival
14%
Adult Patients
14%
Methylation
14%
Outcome Prediction
14%
Molecular Characteristics
14%
Significant Benefit
14%
TP53 mutation
14%
1p/19q Codeletion
14%
Loss of Expression
14%
Radiation Therapy
14%
Retrospective Survey
14%
Time to Progression
14%
Malignant Progression
14%
Infiltrative Glioma
14%
Paclitaxel
14%
Pathologic Characteristics
14%
Hydroxyurea
14%
Pathological Diagnosis
14%
Irinotecan
14%
Astrocytoma
14%
Single-agent Therapy
14%
P53 Status
14%
Oligoastrocytoma
14%
High Proliferation Index
14%
Post-recurrence Survival
14%
Chromosome 9p
14%
MGMT Promoter Methylation
14%
MIB1
14%
WHO Grade II
14%
IDH Status
14%
Irradiation Level
14%
Biochemistry, Genetics and Molecular Biology
Overall Survival
100%
Methylation
66%
Clinical Trial
66%
Proliferative Index
66%
Malignant Transformation
66%
Promoter Region
33%
Progression Free Survival
33%
Chromosome 9p
33%
Hydroxycarbamide
33%
Medicine and Dentistry
Recurrent Disease
100%
Ganglioglioma
100%
Systematic Review
100%
Overall Survival
10%
Carboplatin
10%
Oligodendroglioma
10%
Temozolomide
7%
Malignant Transformation
7%
Oligoastrocytoma
7%
Re-Irradiation
7%
Clinical Trial
7%
Methylation
7%
Neoplasm
3%
Promoter Region
3%
Progression Free Survival
3%
Hydroxyurea
3%
Irinotecan
3%
Disease Predisposition
3%
Chromosome 9p
3%
Paclitaxel
3%
Diseases
3%
Radiation Therapy
3%
Pharmacology, Toxicology and Pharmaceutical Science
Recurrent Disease
100%
Overall Survival
10%
Carboplatin
10%
Oligodendroglioma
10%
Clinical Trial
7%
Temozolomide
7%
Astrocytoma
7%
Malignant Transformation
7%
Hydroxycarbamide
3%
Chemotherapy
3%
Progression Free Survival
3%
Paclitaxel
3%
Disease Predisposition
3%
Irinotecan
3%
Neoplasm
3%
Diseases
3%